Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. Bottino
P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.13-42 Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.13-05 Integrin Β3 Inhibition Enhances the Antitumor Activity of Alk Inhibitor in Alkrearranged NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.13-04 Integrin Β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK Rearranged NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Cancer Research
Cancer Research
Oncology
P1.15-05 the Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
SKLB-287, a Novel Oral Multikinase Inhibitor of EGFR and VEGFR2, Exhibits Potent Antitumor Activity in LoVo Colorectal Tumor Model
Neoplasma
Cancer Research
Antitumor Activity of the Polo-Like Kinase Inhibitor, TAK-960, Against Preclinical Models of Colorectal Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
P3.01-96 Clinical Characteristics of Non–Small Cell Lung Cancer Harboring Mutations in Exon 20 of EGFR or HER2
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary